^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    COX2 inhibitor

    Related drugs:
    Apply
    The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial) (NCT04207944)
    Phase 2
    Duke University
    Active, not recruiting
    Last update posted :
    05/23/2024
    Initiation :
    07/10/2020
    Primary completion :
    04/30/2026
    Completion :
    08/31/2026
    GNAS • MMP9
    |
    GNAS mutation
    The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma (NCT05841550)
    Phase 1/2
    Oslo University Hospital
    Recruiting
    Last update posted :
    11/03/2023
    Initiation :
    05/19/2023
    Primary completion :
    05/19/2027
    Completion :
    05/19/2035
    KRAS • NRAS • IFNG • TNFA • RAS
    |
    KRAS mutation • NRAS mutation • RAS mutation
    |
    Capoxigem (apricoxib) • TG01 vaccine
    Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma (NCT04495894)
    Phase 1
    Emory University
    Recruiting
    Last update posted :
    10/24/2023
    Initiation :
    08/24/2020
    Primary completion :
    10/01/2024
    Completion :
    10/01/2024
    IL6 • TNFA • CXCL8 • IL2 • IL10 • CSF2 • IL1A • IL1B
    |
    IL10 elevation
    Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer (NCT00090974)
    Phase 3
    Eastern Cooperative Oncology Group
    Completed
    Last update posted :
    06/15/2023
    Initiation :
    01/26/2005
    Primary completion :
    01/30/2013
    Completion :
    01/30/2013
    ER • PGR
    |
    PGR positive
    |
    anastrozole • exemestane • celecoxib oral
    J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts (NCT02552394)
    Phase 1
    Weill Medical College of Cornell University
    Completed
    Last update posted :
    04/06/2023
    Initiation :
    07/01/2015
    Primary completion :
    11/14/2019
    Completion :
    01/03/2021
    CYP17A1
    ECP-1014 Treatment for Patients With Solid Tumor Cancers (NCT04930354)
    Phase 1
    Euclises Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    02/16/2023
    Initiation :
    05/01/2023
    Primary completion :
    09/01/2023
    Completion :
    12/01/2023
    PTGS2
    |
    PTGS2 expression
    |
    ECP-1014
    Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study (ERLO-XIB) (NCT02748707)
    Phase 2
    Tata Memorial Hospital
    Active, not recruiting
    Last update posted :
    04/28/2022
    Initiation :
    08/18/2015
    Primary completion :
    02/12/2018
    Completion :
    04/01/2023
    EGFR • TP53
    |
    erlotinib • celecoxib oral
    Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer (HFS) (NCT05327751)
    Phase 3
    Tanta University
    Recruiting
    Last update posted :
    04/14/2022
    Initiation :
    04/01/2022
    Primary completion :
    04/01/2024
    Completion :
    04/01/2025
    TNFA
    |
    capecitabine • celecoxib oral
    COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC (NCT02484664)
    Phase 2
    Brigham and Women's Hospital
    Completed
    Last update posted :
    01/20/2022
    Initiation :
    06/15/2016
    Primary completion :
    11/19/2018
    Completion :
    11/19/2018
    VEGFD
    |
    sirolimus • celecoxib oral
    A Randomized Study of Sulindac in Oral Premalignant Lesions (NCT00299195)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    11/19/2020
    Initiation :
    02/23/2006
    Primary completion :
    01/06/2020
    Completion :
    01/06/2020
    PTGS2
    |
    PTGS2 expression
    Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis (NCT00033371)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    09/29/2020
    Initiation :
    12/13/2001
    Primary completion :
    02/24/2009
    Completion :
    03/24/2009
    BCL2
    |
    celecoxib oral
    Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers (NCT00020878)
    Phase 2
    Jonsson Comprehensive Cancer Center
    Completed
    Last update posted :
    08/03/2020
    Initiation :
    03/01/2001
    Primary completion :
    11/01/2002
    Completion :
    05/01/2009
    PTGS2
    |
    PTGS2 expression
    |
    celecoxib oral
    Meloxicam vs Placebo for Mobilization (NCT02003625)
    Phase 2
    Massachusetts General Hospital
    Completed
    Last update posted :
    05/18/2020
    Initiation :
    10/01/2013
    Primary completion :
    02/01/2019
    Completion :
    04/01/2019
    CD34
    Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma (CELEBRIDO) (NCT03896113)
    Phase 2
    Cliniques universitaires Saint-Luc- Université ...
    Unknown status
    Last update posted :
    01/10/2020
    Initiation :
    11/13/2019
    Primary completion :
    06/30/2022
    Completion :
    06/30/2022
    CD8 • IDO1 • CD4
    |
    IDO1 expression
    |
    celecoxib oral
    Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses (NCT03185871)
    Phase 2
    University of Wisconsin, Madison
    Withdrawn
    Last update posted :
    11/15/2019
    Initiation :
    09/20/2017
    Primary completion :
    10/10/2018
    Completion :
    10/10/2018
    PGR • CD163 • SDC1 • PTGS2 • VIM • CD68
    |
    PGR positive • PTGS2 expression • SDC1 expression
    |
    celecoxib oral
    Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis (NCT00685568)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    11/07/2018
    Initiation :
    11/21/2002
    Primary completion :
    04/21/2006
    Completion :
    04/21/2006
    APC
    |
    APC mutation
    |
    celecoxib oral
    Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia (NCT00052611)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    03/29/2018
    Initiation :
    06/01/2002
    Primary completion :
    03/01/2005
    Completion :
    03/01/2005
    BCL2 • AKT1 • BAX • PTGS2 • CD31 • PECAM1
    |
    BCL2 expression • BAX expression • CD31 expression • PTGS2 expression • VEGFA expression
    |
    celecoxib oral
    Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib (UAB0040) (NCT00582660)
    Phase 2b
    University of Alabama at Birmingham
    Completed
    Last update posted :
    06/15/2017
    Initiation :
    12/01/2001
    Primary completion :
    06/01/2008
    Completion :
    06/01/2008
    CTNNB1 • CEACAM5 • ALOX15
    |
    celecoxib oral
    Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia (NCT00335504)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/15/2017
    Initiation :
    03/01/2006
    Primary completion :
    04/01/2009
    Completion :
    04/01/2009
    CASP3
    |
    atorvastatin
    Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women (NCT00056082)
    Phase 2
    University of Kansas Medical Center
    Completed
    Last update posted :
    02/15/2017
    Initiation :
    01/01/2003
    Primary completion :
    07/01/2008
    Completion :
    07/01/2013
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • ER negative
    |
    celecoxib oral
    Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer (NCT00070057)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    12/29/2016
    Initiation :
    04/01/2003
    Primary completion :
    02/01/2010
    Completion :
    02/01/2010
    MAPK1 • MAPK3
    |
    celecoxib oral
    Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer (NCT00073073)
    Phase 2
    Georgetown University
    Completed
    Last update posted :
    05/17/2016
    Initiation :
    11/01/2003
    Primary completion :
    12/01/2011
    Completion :
    12/01/2011
    BRCA1 • BRCA2 • PCNA • TFF1 • LEP
    |
    BRCA2 mutation • BRCA1 mutation • PCNA expression
    |
    exemestane • celecoxib oral
    Celebrex - Cervix: Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix (NCT00152828)
    Phase 1/2
    University Health Network, Toronto
    Completed
    Last update posted :
    02/09/2016
    Initiation :
    02/01/2001
    Primary completion :
    01/01/2011
    Completion :
    01/01/2011
    VEGFA
    |
    cisplatin • celecoxib oral
    Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma (NCT00596219)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    12/23/2015
    Initiation :
    12/01/2003
    Primary completion :
    10/01/2006
    Completion :
    10/01/2010
    EGFR • IGF1 • IGFBP3
    |
    celecoxib oral
    Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC) (NCT01265576)
    Phase 2
    Vicus Therapeutics
    Unknown status
    Last update posted :
    12/09/2015
    Initiation :
    12/01/2010
    Primary completion :
    02/01/2014
    Completion :
    04/01/2016
    CRP
    |
    sorafenib • propranolol/etodolac (VT-11CR)
    Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NCT00104767)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Completed
    Last update posted :
    10/02/2015
    Initiation :
    01/01/2009
    Primary completion :
    10/01/2014
    Completion :
    10/01/2015
    IL2RA • CD4 • FOXP3 • ISG20
    |
    celecoxib oral
    Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer (NCT00201773)
    Phase 2
    Ohio State University Comprehensive Cancer Center
    Completed
    Last update posted :
    06/30/2015
    Initiation :
    07/01/2003
    Primary completion :
    11/01/2007
    Completion :
    06/01/2011
    ER • PGR
    |
    PGR positive
    |
    exemestane • celecoxib oral